Comparing two drugs for liver inflammation from immunotherapy

This trial tests adding tauroursodeoxycholic acid (a bile acid supplement) to standard immunotherapy (PD-1/PD-L1 drugs) for people with advanced liver cancer that cannot be removed by surgery. It aims to see if the combination works better than immunotherapy alone.

This trial studies a way to treat inflammation of the liver (hepatitis) caused by immune cancer medicines (anti-PD-1/PD-L1, sometimes with anti-CTLA-4) without relying on high-dose steroids. It may help reduce steroid side effects while keeping liver inflammation under control.

This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.

This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.

This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.

This trial tests whether using low-dose steroids can safely manage liver inflammation caused by immunotherapy. It may help patients who have moderate liver problems from their cancer treatment but haven't yet started high-dose steroids.